

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

ESPS manuscript NO: 30218

Title: Immunotherapies in sarcoma: Updates and future perspectives

Reviewer's code: 00723142

Reviewer's country: Oman

Science editor: Jin-Xin Kong

Date sent for review: 2016-09-23 10:40

Date reviewed: 2016-09-23 16:23

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Topic is new and interesting. It is a review of data and trials which need some updating Some of treatment modalities in STS are are not mentioned at all like Trabectedin A lot of new trials and data is coming out now on this subject The language need refinement and polishing

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

ESPS manuscript NO: 30218

Title: Immunotherapies in sarcoma: Updates and future perspectives

Reviewer's code: 00289416

Reviewer's country: Greece

Science editor: Jin-Xin Kong

Date sent for review: 2016-09-23 10:40

Date reviewed: 2016-10-08 16:31

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The present article represents a review on the current therapeutic aspects of the medical treatment of sarcomas. The authors made a commendable effort and accumulated all the recent phase I and II studies of chemotherapeutic agents, biologocial agents including targeted therapies, with a special effort to delineate current and future immunotherapies that have been used to treat sarcomas of various anatomical sites of the human body. After a brief introduction on the clinicostatistical aspects of these rare and intriguing malignant tumors of mesenchymal origin, the authors give an account of the medical treatment of sarcomas from chemotherapy to targeted therapies. They then give an account on the advances in immune-oncology and the other immunotherapeutic modalities used in the non surgical treatment of sarcomas. After, they give an account on the therapeutic vaccines that have been developed for the various histopathological types of sarcomas as well as the immune inhibitors that these agents affect. They conclude that despite all these efforts and advances in the medical treatment surgery continues to be the treatment of choice for sarcomas of the human body in both the soft tissues and the bone types. Chemotherapy and Immunotherapy are still in an experimental level and Radiotherapy has only an adjuvant role in the treatment of these rare



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

malignant tumors. The advances in the treatment of melanomas by immunotherapy gives an optimistic account for the better understanding of onco-immunotherapy principles and may result in the improvement of design in future clinical trials. The article is well written, the references current and up to date, and the language acceptable. The present review therefore can be accepted for publication as submitted.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

ESPS manuscript NO: 30218

Title: Immunotherapies in sarcoma: Updates and future perspectives

Reviewer's code: 00531947

Reviewer's country: Austria

Science editor: Jin-Xin Kong

Date sent for review: 2016-09-23 10:40

Date reviewed: 2016-10-02 22:32

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input checked="" type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The short review on immunotherapies in sarcoma was interesting to read, please find my remarks below. 1. Introduction, "Unfortunately, adjuvant chemotherapy is of little benefit except for..." osteosarcoma is missing, as well as trabectedin for myxoid liposarcomas. Please add "neo-/adjuvant" - as chemo for bone sarcomas is pre- and postop in nearly all cases 2. Please discuss the controversies on Mifamurtide 3. Please check the most recent publications on this topic (2016)